A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2015
At a glance
- Drugs XL 999 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Exelixis
- 16 Feb 2010 Planned end date (1 May 2008) added as reported by ClinicalTrials.gov.
- 23 Apr 2008 Status changed from suspended to discontinued, reported by ClinicalTrials.gov. The trial was discontinued due to safety concerns.
- 09 Jan 2008 Status changed from recruiting to suspended according to ClinicalTrials.gov.